Preferred Name |
pegvisomant |
|
Synonyms |
B-2036 PEG Somavert B2036-PEG |
|
ID |
http://purl.bioontology.org/ontology/MESH/C406545 |
|
altLabel |
B-2036 PEG Somavert B2036-PEG |
|
cui |
C1174777 C0768710 C0913469 |
|
Has mapping qualifier | ||
HM |
D019382/Q000031 |
|
II |
D011986/Q000037 D000172 |
|
Inverse of RB |
N824AOU5XV 0 |
|
LT |
TRD |
|
Mapped to | ||
MDA |
20000418 |
|
MeSH Frequency |
413 |
|
MMR |
20160826 |
|
notation |
C406545 |
|
prefLabel |
pegvisomant |
|
SC |
1 |
|
Scope Statement |
is a genetically engineered analogue of human growth hormone that functions as a growth hormone-receptor antagonist; used to treat Acromegaly; |
|
SRC |
N Engl J Med 2000 Apr 20;342(16):1171-7 |
|
TERMUI |
T535026 T412077 T336434 T336435 |
|
TH |
US NLM (2000) FDA SRS (2017) INN (19XX) DE |
|
tui |
T125 T116 T121 |
Create mapping